What Shattuck Labs does

Shattuck Labs, Inc. is a clinical-stage biotechnology company founded in 2016 and headquartered in Austin, Texas, with R&D operations in Durham, North Carolina. The company develops biologic medicines that target the TL1A/DR3 signaling axis for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases, having pivoted from an earlier oncology focus. Its lead asset, SL-325, is described as the first DR3 blocking antibody to enter human clinical trials, engineered with picomolar binding affinity, high epitope specificity (avoiding cross-binding to decoy receptor 3), Fc-silencing to minimize immune complex formation and anti-drug antibody (ADA) development, and durable receptor occupancy exceeding three months. The pipeline also includes SL-425, an extended half-life variant of SL-325, and SL-846, a DR3 x IL-23R bispecific antibody combining DR3 blockade with IL-23 receptor inhibition in a single half-life extended format; both are in IND-enabling stages.

SL-325 has completed Phase 1 enrollment of 72 healthy volunteers with reported 3.7% ADA development, complete DR3 receptor occupancy at doses of 0.1 mg/kg and above, and no serious treatment-emergent adverse events across all dose levels. The company plans to initiate the Phase 2b RECEPTIVE-CD1 trial in Crohn's disease (planned enrollment ~174 patients) across U.S., Canadian, and European sites in Q3 2026, with later-stage trials expected to expand into ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa.

Shattuck is publicly traded on NASDAQ under the ticker STTK (IPO completed 2020) and is pre-revenue, generating no commercial product sales. Its business model is one of clinical development with future revenue contingent on regulatory approval and commercialization of its drug candidates, planned for distribution through standard pharmaceutical wholesale channels targeting gastroenterologists and inflammatory disease specialists. As of Q1 2026, the company reported $90.4 million in cash and investments (versus $78.1 million as of December 31, 2025), a Q1 2026 net loss of $14.8 million, and a full-year 2025 net loss of $48.8 million. Recent financing activity includes a $103 million OrbiMed-led private placement (August 2025), a $50 million public offering (December 2023), and a $75 million public offering (June 2026), with stated cash runway extending into 2029.

Name

Shattuck Labs

Legal name

Shattuck Labs, Inc.

Website

https://shattucklabs.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Shattuck Labs is a clinical-stage biotechnology company developing first-in-class DR3 blocking antibodies that target the TL1A/DR3 pathway for treating inflammatory bowel disease and other autoimmune conditions, with lead candidate SL-325 advancing through Phase 1/2 clinical trials.

Ownership category

akta.pro rank

Product category

Biologic Therapeutics for Inflammatory and Immune-Mediated Diseases

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

Keywords

• Inflammatory bowel disease therapeutics
• Monoclonal antibody development
• DR3 blocking antibodies
• Biologic medicines pipeline
• Clinical-stage biotechnology

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others, Marketing or Sales

Revenue model

1. Biopharmaceutical development: Pre-revenue clinical-stage biotech company. Revenue will be generated from commercialization of drug candidates upon regulatory approval. Currently advancing SL-325 through clinical trials for inflammatory bowel disease.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Shattuck Labs develops monoclonal antibody therapies that block the DR3 receptor to inhibit TL1A-driven inflammation, with lead candidate SL-325 advancing through Phase 1/2 clinical trials for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Its pipeline also includes SL-425 (half-life extended DR3 blocker, IND-enabling) and SL-846 (DR3 x IL-23R bispecific antibody, IND-enabling). All candidates are investigational and the company is pre-revenue.

Product overview

Shattuck Labs is a clinical-stage biotechnology company developing a pipeline of novel biologic therapies designed to block the TL1A/DR3 pathway. The company's lead program is SL-325, a first-in-class DR3 blocking antibody currently in Phase 1 clinical trials for inflammatory bowel disease (IBD). Additional pipeline programs include SL-425 (half-life extended version of SL-325) and SL-846 (DR3 x IL-23R bispecific antibody), both in IND-enabling stages. The company's approach focuses on receptor blockade of DR3, which they believe may deliver superior efficacy compared to targeting the TL1A ligand, with potentially reduced immunogenicity due to avoiding immune complex formation.

Differentiator

Problem solved

Functional benefit

Products and services

• SL-325 SL-325 is a first-in-class DR3 blocking monoclonal antibody targeting the TL1A/DR3 pathway for the treatment of inflammatory bowel disease (IBD) and other inflammatory/immune-mediated diseases. It is engineered with picomolar binding affinity to DR3, epitope specificity that does not cross-bind to decoy receptor 3 (DcR3), Fc-silencing to prevent unwanted immune activation, and no DR3 internalization enabling durable receptor occupancy exceeding three months. Phase 1 data demonstrated only 3.7% anti-drug antibody development versus reportedly 100% for some TL1A-directed bispecifics. Intended for moderate-to-severe Crohn's disease and ulcerative colitis patients who have failed existing therapies.
• SL-425 SL-425 is a half-life extended version of SL-325 (DR3 blocking antibody). Shattuck may select to advance SL-325 and/or SL-425 in future studies based on pharmacokinetic and pharmacodynamic properties, with each antibody offering potentially different advantages in distinct diseases and administration regimens. Currently in IND-enabling stage with indications to be determined.
• SL-846 (DR3 x IL-23R bispecific antibody) SL-846 is a potentially first-in-class DR3 x IL-23 receptor blocking bispecific antibody that pairs DR3 blockade with IL-23R inhibition in a single, half-life extended bispecific antibody format. The dual-targeting design targets improved efficacy over monotherapy approaches for inflammatory bowel diseases and inflammatory skin diseases. Currently in IND-enabling stage with indications to be determined.

Quantifiable outcome

• Only 3.7% of subjects developed antidrug antibodies in Phase 1 trial
• +3 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators13 records

Recent moves1 record

Broad incumbents

• AbbVie: AbbVie markets Humira, Skyrizi, and Rinvoq for IBD and dominates the inflammatory bowel disease market. As the incumbent franchise leader, it competes with Shattuck for the same moderate-to-severe Crohn's and ulcerative colitis patients.
• Eli Lilly: Eli Lilly acquired Morphic Therapeutic for ~$3.2B in 2024 to access MORF-057, an oral α4β7 inhibitor for IBD. Lilly is a broad incumbent in immunology with multiple Phase 3 IBD programs and competes with Shattuck in the inflammatory bowel disease market.
• Johnson & Johnson: Johnson & Johnson markets Stelara and Tremfya for IBD, two of the leading IL-23 pathway biologics. It is a broad incumbent competing with Shattuck for moderate-to-severe Crohn's disease and ulcerative colitis patients.
• Pfizer: Pfizer acquired Arena Pharmaceuticals and markets etrasimod (Velsipity) for ulcerative colitis. Pfizer is a broad incumbent with multiple IBD and immunology assets competing with Shattuck's SL-325 in moderate-to-severe IBD.

Direct peers

• Merck & Co. Merck is developing tulisokibart (MK-7240), an anti-TL1A monoclonal antibody acquired via the $10.8B Prometheus Biosciences deal, currently in Phase 3 for IBD. It is the most clinically advanced direct competitor to Shattuck's SL-325 in the same inflammatory bowel disease indication.
• Sanofi: Sanofi is developing amlitelimab, an anti-TL1A monoclonal antibody in late-stage clinical trials for IBD and other inflammatory diseases. Sanofi competes directly with Shattuck in targeting the TL1A/DR3 axis for IBD and atopic dermatitis indications.
• Takeda Pharmaceutical: Takeda acquired Maverix Therapeutics and is developing a TL1A-directed antibody for IBD, putting it in direct competition with Shattuck in the same molecular pathway and indication. Takeda's larger commercial footprint in gastroenterology makes it a significant competitor.
• Roche: Roche is developing an anti-TL1A antibody (RG6631) for inflammatory bowel disease and other immune-mediated conditions. It competes directly with Shattuck in the TL1A/DR3 pathway for IBD with substantially greater resources and commercial reach.

Emerging players

• Bristol-Myers Squibb: Bristol-Myers Squibb markets Zeposia (ozanimod), an oral S1P receptor modulator approved for ulcerative colitis. It is an emerging competitor in the IBD space alongside Shattuck's biologic SL-325, particularly competing for patients seeking oral alternatives.

Others

• Morphic Therapeutic: Morphic was a clinical-stage biotech developing MORF-057, an oral α4β7 integrin inhibitor for IBD, acquired by Eli Lilly in 2024 for ~$3.2B. It serves as a relevant transaction precedent for valuation and as a former direct peer in the IBD clinical-stage biotech category.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/shattuck-labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shattuck Labs